文献速递心力衰竭与心肌病

沙库巴曲缬沙坦在射血分数降低心衰合并不同肾脏风险患者中的疗效

Effects of Sacubitril/Valsartan Across the Spectrum of Renal Impairment in Patients With Heart Failure.
PubMed 文献 · J Am Coll Cardiol · 2024-04-06

基于PARADIGM-HF试验中1910例有数据患者的分析,按KDIGO风险分层评估沙库巴曲缬沙坦的疗效。结果显示,高/极高KDIGO风险患者主要复合终点发生率最高,而沙库巴曲缬沙坦在各级肾脏风险中均显示一致的获益和安全性。

要点

  • 约1/4的HFrEF患者属于KDIGO高/极高肾脏风险,其心血管事件风险最高。
  • 沙库巴曲缬沙坦在KDIGO低、中、高/极高风险组中主要终点获益一致(PInteraction=0.31)。
  • 沙库巴曲缬沙坦在各级肾脏风险中肾脏复合终点获益一致(PInteraction=0.50)。

核心结论

  • 在HFrEF患者中,沙库巴曲缬沙坦在KDIGO肾脏风险谱中表现出一致的心血管和肾脏保护获益及安全性。

研究设计与样本

  • PARADIGM-HF为全球随机对照试验,比较沙库巴曲缬沙坦与依那普利在HFrEF患者中的疗效。
  • 本分析纳入1910例(占总23%)有数据患者,按KDIGO低、中、高/极高风险分类。

主要发现

  • 低、中、高/极高KDIGO风险组分别占42%、32%、26%。
  • 主要复合终点(心血管死亡或心衰住院)发生率分别为7.6、9.4、14.9每100人年(P<0.001)。
  • 沙库巴曲缬沙坦对主要终点和肾脏复合终点的效应在各KDIGO风险组间无显著交互作用(PInteraction分别为0.31和0.50)。

关键数值与推荐

  • KDIGO风险分类整合估计肾小球滤过率和尿白蛋白肌酐比。
  • 主要终点为心血管死亡或心衰住院的复合终点。
  • 肾脏复合终点定义为eGFR持续下降≥40%或终末期肾病。

临床怎么用

  • 支持在广泛肾脏风险范围的HFrEF患者中启动沙库巴曲缬沙坦治疗。

局限性

  • 分析仅纳入1910例(占总23%)有数据患者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The Kidney Disease Improving Global Outcomes (KDIGO) classification integrates both estimated glomerular filtration rate and urine-albumin-creatinine ratio to stratify risk more comprehensively in patients with chronic kidney disease. There are limited data assessing whether this classification system is associated with prognosis and treatment response in heart failure populations. OBJECTIVES: The aim of this study was to evaluate the relative treatment effects of sacubitril/valsartan across the KDIGO risk categories in patients with HFrEF. METHODS: PARADIGM-HF (Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure) was a global randomized controlled trial evaluating sacubitril/valsartan vs enalapril in patients with heart failure with reduced ejection fraction (HFrEF). Patients were classified according to low, moderate, and high/very high KDIGO risk. Treatment responses were assessed according to baseline KDIGO risk. The primary outcome was a composite of cardiovascular (CV) death or heart failure hospitalization. A renal composite outcome was defined as sustained decline in estimated glomerular filtration rate by ≥40% or end-stage kidney disease. RESULTS: Among 1,910 (23% of total) participants with available data, 42%, 32%, and 26% were classified as low, moderate, and high/very high KDIGO risk, respectively. Patients in the highest KDIGO risk categories experienced the highest rates of the primary composite outcome (7.6 per 100 person-years [95% CI: 6.5-9.0 per 100 person-years], 9.4 per 100 person-years [95% CI: 7.9-11.2 per 100 person-years], and 14.9 per 100 person-years [95% CI: 12.7-17.6 per 100 person-years]; P < 0.001). Sacubitril/valsartan had a similar safety profile and demonstrated consistent effects on the risk of both the primary outcome (PInteraction = 0.31) and the renal composite outcome (PInteraction = 0.50) across the spectrum of KDIGO risk. CONCLUSIONS: One in 4 patients with HFrEF were classified as at least high KDIGO kidney risk; these individuals faced concordantly the highest risks of CV events. Sacubitril/valsartan exhibited consistent CV and kidney protective benefits as well as safety across the spectrum of baseline kidney risk. These data further support initiation of sacubitril/valsartan in HFrEF across a broad range of kidney risk. (This Study Will Evaluate the Efficacy and Safety of LCZ696 Compared to Enalapril on Morbidity and Mortality of Patients With Chronic Heart Failure [PARADIGM-HF]; NCT01035255).

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Chatur, Neuen, Claggett, et al. Effects of Sacubitril/Valsartan Across the Spectrum of Renal Impairment in Patients With Heart Failure. J Am Coll Cardiol. 2024. PMID: 38588927. doi:10.1016/j.jacc.2024.03.392

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。